Anthony Mancini Sells 1,774 Revolution Medicines (RVMD) Shares at $199.30 Each

Anthony Mancini, an insider of Revolution Medicines, Inc. (RVMD), sold 1,774 shares at $199.30 per share, totaling $353,449 on September 20, 2026.

Who is Anthony Mancini and What is His Real Role at Revolution Medicines, Inc.

According to available information, the "See Remarks" field appears in the official form, indicating that Anthony Mancini's specific role is not detailed in the public document. In publicly traded companies, individuals listed on Form 4 are typically executives, board members, or members of the executive committee, all having direct access to the company's financial and strategic information. This access includes sales forecasts, clinical trial results, capital allocation decisions, and partnership projects that have not yet been made public.

Being listed as an insider means that Anthony Mancini is subject to the transparency requirements imposed by the Securities and Exchange Commission (SEC). Each transaction involving the company's shares must be reported within two business days of the trade, as per Form 4 regulations. This requirement aims to ensure that the market has immediate visibility into insider movements, thereby limiting risks of insider trading abuses. Individual investors can review these filings to assess the activity of those closest to the management.

Transaction Details: 1,774 Shares at $199.30 Each

The filing indicates that the sale involved 1,774 shares of Revolution Medicines, Inc., each sold at a price of $199.30. The total gross value of the transaction amounts to $353,449, calculated by multiplying the number of shares by the per-share price. It is important to distinguish between the per-share price ($199.30) and the total value ($353,449), as these two measures reflect different aspects of the transaction: the former indicates the market price at the time of sale, while the latter represents the actual amount of money received by the insider.

The date of the transaction, September 20, 2026, corresponds to the filing date of Form 4 on the SEC's EDGAR website, as shown in the official URL: https://www.sec.gov/Archives/edgar/data/2124509/000212450926000008/0002124509-26-000008-index.htm. This temporal transparency allows observers to compare the transaction price with the stock's closing price on the same day to determine whether the insider sold at a premium or discount to market value.

Why Insiders Sell Their Shares – Possible Reasons

Insider sales can result from several motivations that are not necessarily linked to the company's future performance. Portfolio diversification is a common reason: an executive may decide to reduce their exposure to a single stock to mitigate overall risk. Tax planning also plays a significant role, particularly when an insider seeks to realize capital gains before the end of a fiscal year or take advantage of a more favorable tax bracket.

Personal liquidity needs, such as funding a real estate purchase, paying off debt, or financing education, may lead an insider to monetize part of their shares. Finally, the sale may be perceived as a bearish signal by the market, but this interpretation should be nuanced: the decision may purely financial and unrelated to changes in the company's operational prospects. Insiders are free to sell for private reasons, and no definitive conclusion should be drawn solely from this movement.

How Individual Investors Monitor Form 4 Filings

The SEC's EDGAR website is the official source where Form 4 filings are published. Investors can access these documents for free by searching for the ticker RVMD or the company name. Several third-party platforms aggregate this data and offer email alerts or interactive dashboards, facilitating daily monitoring of insider movements.

It is advisable, however, to combine Form 4 analysis with other indicators, such as quarterly reports, press releases, and sector analyses. The information contained in Form 4 filings is limited to size, price, and date of the transaction, without providing detailed justification for the insider's decision. Thus, investors should remain cautious and not base their buy or sell strategies solely on these filings.